Profarma Distribuidora de Produtos Farmaceuticos SA

As of June 30, 2026, Profarma Distribuidora de Produtos Farmaceuticos SA carries a market capitalization of 833.75M, placing it among publicly traded companies globally. Its enterprise value stands at 2.49B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Profarma Distribuidora de Produtos Farmaceuticos SA has 122.61M shares outstanding.

As of June 30, 2026, Profarma Distribuidora de Produtos Farmaceuticos SA trades at a trailing price-to-earnings ratio of 5.40. The price-to-sales ratio is 0.07, and the price-to-book ratio stands at 0.58.

As of June 30, 2026, Profarma Distribuidora de Produtos Farmaceuticos SA trades at an EV/EBITDA multiple of 3.70 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.20 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 5.43 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Profarma Distribuidora de Produtos Farmaceuticos SA trades at an EV/FCF ratio of 3.93, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 2.49B versus a market cap of 833.75M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Profarma Distribuidora de Produtos Farmaceuticos SA maintains a current ratio of 1.37, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 112.64, indicating elevated leverage, while an interest coverage ratio of 2.89 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 1.72M in revenue per employee across its workforce of 7,269.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Profarma Distribuidora de Produtos Farmaceuticos SA recorded 25.10M in income tax expense. That works out to an effective tax rate of 13.47, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 186.28M, leaving 154.54M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Profarma Distribuidora de Produtos Farmaceuticos SA's stock has gained approximately 36.70% over the past 52 weeks. The 50-day moving average sits at 7.88, while the 200-day moving average is 7.66.

Over the twelve months ended June 30, 2026, Profarma Distribuidora de Produtos Farmaceuticos SA generated 12.49B in revenue and converted that into 154.54M in net income, yielding earnings per share of 1.31. EBITDA reached 672.58M, while operating income came in at 458.05M.

As of June 30, 2026, Profarma Distribuidora de Produtos Farmaceuticos SA holds 487.77M in cash and equivalents against 1.90B in total debt, resulting in a net debt position of 855.41M. Total book value stands at 1.44B, with working capital of 1.55B providing operational flexibility.

Profarma Distribuidora de Produtos Farmaceuticos SA produced 573.09M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -141.85M in capital expenditures, free cash flow totaled 431.24M - equivalent to 3.52 per share.

Over the twelve months ended June 30, 2026, Profarma Distribuidora de Produtos Farmaceuticos SA posted a gross margin of 15.14, reflecting its pricing power and cost economics. The operating margin of 3.67 and net profit margin of 1.24 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Profarma Distribuidora de Produtos Farmaceuticos SA paid dividends of 0.32 per share. The dividend payout ratio of 23.24 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 51.72, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 17.10, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Profarma Distribuidora de Produtos Farmaceuticos SA shareholders.

Profarma Distribuidora de Produtos Farmaceuticos SA's most recent stock split took place on January 11, 2018 with a 818:855 split ratio.

As of June 30, 2026, Profarma Distribuidora de Produtos Farmaceuticos SA has an Altman Z-Score of 2.27, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.